Barely Significant
← all phrases

“a numerical trend”

1,013 sentences · 1,013 papers · 1,817 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

a numerical trendP = 0.1933.9× alphagold
Additional exploratory analyses of patients with infective endocarditis/cardiac abscess as their source of infection also demonstrated no significant difference in 90-day mortality rates between early versus late initiation cohorts, although there was a numerical trend in favor of initiation on or before day five (37.8% versus 52.2% respectively, P = 0.193).
a numerical trendP = .204.0× alphagold
31 There was also a numerical trend toward a reduced incidence of TLR with DCB (3.4% vs 10.3%; P = .20), but the difference was not statistically significant owing to the limited statistical power. 31 More recently, in the BASKET-SMALL 2 (Basel Kosten Effektivitäts Trial-DCBs versus Drug-eluting Stents in Small Vessel Interventions 2
Coronary Drug-Coated Balloons for De Novo and In-Stent Restenosis Indications.
J Soc Cardiovasc Angiogr Interv · 2023 · PMC11308150
a numerical trendp = 0.36.0× alphagold
Changes in the perceived importance of a healthy diet and social support were not significant, but effect sizes suggested a numerical trend towards an advantage over the control group at four months (M difference importance = 0.1, p = 0.3, d = 0.3; M difference social support = 0.3, p = 0.08, d = 0.4).
a numerical trendp = 0.3336.7× alphagold
Compared with IgAN patients, AAGN demonstrated significantly elevated uNAG levels (22.60 [14.00, 33.40] vs 14.40 [8.80, 22.10] U/gcr, p = 0.006), with a numerical trend toward higher uNGAL concentrations (29.30 [15.76, 45.14] vs 25.17 [13.52, 38.08] ng/mL, p = 0.333) and reduced urinary specific gravity (1.01 ± 0.01 vs. 1.02 ± 0.01, p = 0.132).
a numerical trendp=0.3346.7× alphagold
In the ≥65 years subgroup, statistically significant improvements from baseline in trough FVC were observed with FF/VI versus placebo at Days 2, 7, 14, 28, and 56, with a numerical trend in favor of FF/VI at Days 84, 112, 140, and 168 ( Supplementary Figure 2B ), and the end of the study (45 mL; p=0.334) ( Table 4 ).
a numerical trendP = .346.8× alphagold
In an exploratory comparison, PFS did not differ significantly between patients receiving polatuzumab vedotin– and platinum-based bridging chemotherapy, although a numerical trend toward improved outcomes was observed in the polatuzumab vedotin–based group across the different products (tisa-cel [HR, 0.82; P = .34]; liso-cel [HR, 0.72; P = .34]; supplemental Figure 2 ).